Bevacizumab is an antibody that attacks the vascular endothelial growth factor (VEGF) antigen and is approved by the US Food and Drug Administration (FDA) for the treatment of colorectal cancer and glioblastoma. The gene discussed is VEGFA; the disease is colorectal cancer.